(Q46126666)

19 December 2017

title

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide (English)

1 reference

19 December 2017

1 reference

Violetta Dziedziejko

5

0 references

Marek Drozdzik

Marek Drozdzik

6

0 references

Andrzej Pawlik

Andrzej Pawlik

1

0 references

Krzysztof Safranow

Krzysztof Safranow

4

0 references

Mateusz Kurzawski

3

Mateusz Kurzawski

1 reference

19 December 2017

author name string

Magdalena Herczynska

2

1 reference

19 December 2017

publication date

1 February 2009

1 reference

19 December 2017

published in

Pharmacogenomics

1 reference

19 December 2017

volume

10

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

303-309

1 reference

19 December 2017

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

The cellular location of dihydroorotate dehydrogenase: Relation to de novo biosynthesis of pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Protein import into mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Dihydroorotate dehydrogenase mRNA and protein expression analysis in normal and drug-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Biogenesis of mitochondrial proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Protein sorting to mitochondria: evolutionary conservations of folding and assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

Severe pyridine nucleotide depletion in fibroblasts from Lesch-Nyhan patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.303

10.2217/14622416.10.2.303

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017